• Alfuzosin HCl: Gastroretentive Research Workflows

  2026-09-08

  Use Alfuzosin HCl to connect α1-receptor pharmacology with measurable lower urinary tract function and formulation performance. This guide translates gastroretentive sponge findings into practical preparation, release-testing, analytical, and troubleshooting workflows.

• AhR–RBX1–HSF1 Signaling in Acute Pancreatitis

  2026-09-07

  The reference study identifies an AhR–RBX1–HSF1 regulatory axis that links pancreatic stress responses, tight-junction integrity, and macrophage polarization during acute pancreatitis. Its combination of animal modeling, primary-cell experiments, interaction prediction, and pharmacological counter-perturbation provides a useful framework for testing pathway dependence while also highlighting unresolved directionality within the reported HSF1 mechanism.

• Bicinchoninic Acid Assay: BCA Kit Guide

  2026-09-07

  The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit, SKU K4102, provides total-protein measurement for dilute samples, including many detergent-containing preparations and cell lysates. It is intended for scientific research and sample-normalization workflows, not diagnostic, clinical, or medical testing.

• KPT-330 Combinations in Triple-Negative Breast Cancer

  2026-09-05

  Rashid and colleagues used drug screening, synergy testing, patient-derived xenografts, and transcriptomic analyses to identify KPT-330-based combinations for basal-like triple-negative breast cancer. The strongest preclinical result was enhanced tumor control with KPT-330 plus the PI3K/mTOR inhibitor GSK2126458, supported by evidence that XPO1 is highly expressed and clinically relevant in basal-like disease.

• Roscovitine in Immune-Enabled Tumor Models

  2026-09-04

  Roscovitine (Seliciclib) offers a mechanistic way to separate tumor-cell cycle effects from immune-mediated tumor control. This article shows how to integrate CDK perturbation with radiotherapy, checkpoint blockade, and abscopal-effect assays without overstating combination evidence.

• Levofloxacin as a Resistance-Aware Research Probe

  2026-09-04

  Levofloxacin can connect bacterial DNA replication pathway studies with carefully controlled bone-cell assays. This evidence-led guide uses plasmid transmission data to improve experimental controls, interpretation, and translational boundaries.

• Pregnancy, LNP Structure, and mRNA Delivery

  2026-09-03

  The PNAS study shows that lipid nanoparticle chemistry and administration route jointly determine mRNA expression, inflammatory signaling, placental cell targeting, and postnatal growth in pregnant mice. Its central contribution is a mechanism-based framework for separating delivery potency from immunological cost when designing RNA therapies for pregnancy-related conditions.

• PDGF-BB Workflow for Smooth Muscle Assays

  2026-09-03

  Build a controlled cell proliferation assay with murine recombinant PDGF-BB, then connect mitogenic responses to the metabolic and mitochondrial remodeling described in pulmonary hypertension research. This guide combines product handling, dose-finding logic, orthogonal readouts, and troubleshooting for more reproducible vascular biology experiments.

• LLY-507: A Compartment-Aware SMYD2 Strategy

  2026-09-02

  LLY-507 is a selective SMYD2 inhibitor for dissecting methyltransferase-dependent signaling in cancer and renal fibrosis models. This article presents an evidence-calibrated strategy that connects substrate selectivity, cellular compartment, orthogonal assays, and translational limitations.

• BCECF-AM: Turning pH Into Translational Insight

  2026-09-02

  BCECF-AM converts intracellular pH from a hidden variable into a decision-ready phenotype. This thought-leadership guide connects ratiometric imaging with secretion biology, cross-species validation, assay strategy, and translational interpretation.

• Cy3 TSA Fluorescence System Kit for HCC Imaging

  2026-09-01

  The Cy3 TSA Fluorescence System Kit converts weak HRP activity into a dense, localized fluorescent deposit for IHC, ICC, and ISH. Its strongest use-case is resolving low-abundance targets such as regulatory RNAs or metabolic proteins in fixed HCC cells and tissues when conventional fluorescence microscopy detection is insufficient.

• WST-8 Glucose Uptake Assay Kit in Delivery Studies

  2026-09-01

  The WST-8 Glucose Uptake Assay Kit provides a non-radioactive way to connect ion-tuned CPP/nucleic acid delivery with cellular metabolic phenotype. This guide explains the assay mechanism, controls, interpretation limits, and experimental decisions needed to distinguish altered glucose handling from delivery-related cytotoxicity.

• Triamcinolone B1859: Practical Lab Guide

  2026-08-31

  Triamcinolone (B1859) is a synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid signaling, inflammation, and immunosuppression. This guide covers solvent selection, storage, assay setup, and quality control while defining why the compound should not be used for diagnostic, clinical, or therapeutic applications.

• N-MYC–eIF4G1 Survival Axis in inv(16) AML

  2026-08-31

  Peramangalam et al. identify a previously unrecognized MYCN enhancer and show that N-MYC sustains inv(16) acute myeloid leukemia through the translation-initiation factor eIF4G1. By integrating transcriptomic analysis, enhancer studies, functional perturbation, and patient-derived xenograft models, the study connects CBFβ-SMMHC-associated transcriptional deregulation with leukemic cell survival.

• Paclitaxel (Taxol) in TNBC Assay Design

  2026-08-30

  Paclitaxel and Taxol remain essential tools for cancer research, but their greatest value emerges when microtubule phenotypes are connected to subtype-specific resistance biology. This guide develops a resistance-aware assay framework for breast cancer research, informed by a key study of ceritinib and paclitaxel in triple-negative breast cancer.

8024 records 1/535 page Next 12345 下5页 Last page